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Background: Thrombosis and immune dysfunction are two important complications that result from the
administration of parenteral nutrition. Endothelial cells within the vasculature are crucial components necessary for
maintenance of normal coagulation and immune function.
Methods: We compared the effects of three commercial lipid emulsions (LEs; Intralipid®, ClinOleic® [or Clinolipid®],
and Omegaven®) differing in the levels of omega-6 polyunsaturated fatty acids, omega-3 polyunsaturated fatty
acids, omega-9 monounsaturated fatty acids, and saturated fatty acids upon endothelial cell fatty acid composition
using Gas chromatography, endothelial cell integrity by assessing measurement of apoptosis and necrosis using
flow cytometry, endothelial cell inflammatory activation by assessing the induction of ICAM-1 by lipopolysaccharide
[LPS]), and transcription factor activation (phosphorylation of NF-κB) using western blot analysis.
Results: Gas chromatographic analysis confirmed cellular uptake of the fatty acids within the LEs; furthermore,
these fatty acid changes reflected the composition of the oils and egg phosphatides used in the manufacturing of
these emulsions. However, the kinetics of fatty acid uptake and processing differed between LEs. Fish oil LE
negatively impacted cell viability by doubling the percentage of apoptotic and necrotic cell populations quantified
by flow cytometry using Annexin V/Fluorescein and propidium iodide. The soybean oil LE did not alter cell viability,
while the olive oil-predominate emulsion improved cell viability. All LEs were capable of suppressing LPS-induced
ICAM-1 expression; however, the fish oil LE was more potent than the other emulsions. Fish oil LE supplementation
of cells also suppressed LPS-induced phosphorylation of NF-κB, while the soybean oil and olive predominant LE
had no effect upon NF-κB phosphorylation.
Conclusions: Lipid emulsions are readily incorporated and stored in the form of triacylglycerols. Soybean oil-based,
olive oil-predominant and fish-oil based LEs differentially affected endothelial cell integrity. Importantly, these three
LEs were capable of suppressing endothelial cell inflammatory response despite their fatty acid content.
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Parenteral nutrition is an important therapeutic modality
for the maintenance of nutritional status in patients with
dysfunctional gastrointestinal tracts. Lipid is one compo-
nent of the optimal nutritional intake of these patients
and supplies both needed energy and essential fatty acids
to the patients. Two important complications from the
administration of parenteral nutrition are thrombosis
and immune dysfunction [1,2]. The vascular endothelial
cell is instrumental in the pathogenicity of both these
complications [3]. Vascular endothelium plays a key role
in hemostasis, regulation of vessel tone and tissue blood
flow, oxygen and nutrient transport into the tissues, vas-
cular permeability, and inflammation [3,4].
Vascular endothelial integrity is important for the
maintenance of anti-coagulation factors on the surface
of blood vessels and minimization of coagulation activa-
tion. Endothelial cell apoptosis is implicated in the
pathogenicity of thrombosis [5]. Free fatty acids have
multiple effects upon endothelial cells that include in-
duction of apoptosis and /or necrosis [5-9]. However,
the effects of complex fatty acid formulations such as
commercial lipid emulsions (LEs), which are based upon
mixtures of soybean, olive, coconut, and fish oils upon
endothelial cell integrity (apoptosis and necrosis), have
not previously been examined.
Endothelial cells also form an important component of
the inflammatory and immune response systems and are
one of the first cells to be activated during inflammation.
Endothelial cell activation promotes leukocyte binding
and transmigration at sites of inflammation via induc-
tion of adhesion molecules such as intercellular adhesion
molecule-1 (ICAM-1) [10-12]. Inflammation-induced
ICAM-1 expression has been linked to activation of the
transcription factor, nuclear factor kappa B (NF-κB), by
various inflammatory stimuli (i.e., lipopolysaccharide
[LPS], tumor necrosis factor-alpha [TNFα], and
interleukin-1 beta [IL-1β]). Most studies of vascular
endothelial cell inflammatory activation have been per-
formed using cultured endothelial cells with purified
individual free fatty acids [8,9,13-15]. However, the
studies using individual free fatty acids may not reflect
the performance of complex LEs that contain mixtures
of various fatty acids.
The objective of this study was to expand our know-
ledge of the effects of LEs, as opposed to free fatty acids,
upon endothelial cell functions. We were particularly in-
terested in those endothelial cell functions that related
to thrombosis and inflammatory activation. In addition,
we were interested in evaluating the effects of the LEs
upon potential endothelial cell signaling pathways in-
volved in thrombosis and inflammation. We compared
the effects of three common commercial LEs differing in
the levels of omega-6 polyunsaturated fatty acids (n-6PUFA), omega-3 polyunsaturated fatty acids (n-3 PUFA),
omega-9 monounsaturated fatty acids (n-9 MUFA), and
saturated fatty acids upon endothelial cell fatty acid up-
take and composition, endothelial cell integrity (assessed
by measurement of apoptosis and necrosis), endothelial
cell inflammatory activation (assessed through the
induction of ICAM-1 by LPS), and transcription factor
activation (phosphorylation of NF-κB). This is the first
study to directly compare the three major classes of
commercial LEs (i.e., soybean oil-based LE, olive oil-
based LE, fish oil-based LE) upon these endothelial cell
parameters and is the first study to evaluate the effects
of LEs upon endothelial cell apoptosis/necrosis and NF-
κB activation via phosphorylation. In addition to the
varying fatty acid content present in the emulsions, these
commercially available products also differ in tocoph-
erol, tocotrienol, and sterol composition [16-18]. Our
pre-study hypothesis was that the n-6 PUFA predom-
inant LE (soybean oil) would enhance the endothelial
NF-κB and ICAM-1 response to LPS (a pro-inflammatory
response), the n-3 PUFA predominant LE (fish oil)
would suppress the NF-κB and ICAM-1 response (an
anti-inflammatory response), and the n-9 MUFA pre-
dominant LE (i.e., olive oil) would have a neutral effect
on endothelial cell NF-κB activation and ICAM-1
response.Methods
Materials
Human-derived aortic endothelial cells (HAECs), endo-
thelial basal medium-2 (EBM-2), and the endothelial
growth medium-2 microvascular (EGM-2MV) bullet kit
materials were purchased from Lonza Incorporated
(Walkersville, MD). Fetal bovine serum (FBS) and all
electrophoresis products were purchased from Life
Technologies (Grand Island, NY). Reagents, chemicals,
and the Oil Red O staining kits were acquired from
Sigma Chemical Company (St. Louis, MO). Consumable
tissue culture products were obtained from Fisher Sci-
entific (Pittsburgh, PA). The Annexin V FLUOS staining
kits were purchased from Roche Applied Science (In-
dianapolis, IN). Gas chromatography standards were
acquired from Restek Corporation (Bellefonte, PA).
Fluorescently coupled antibodies were obtained from
BD Pharmingen (San Diego, CA). Western blot anti-
bodies were purchased from Cell Signaling Technology
(Danver, MA).Human aortic endothelial cell culture
Human aortic endothelial cells (HAECs) were main-
tained in EMB-2 supplemented with bullet kit materials
and 5% FBS. Cells were maintained at 37°C in 5% CO2
in a humidified atmosphere. Endothelial cell cultures in
Harvey et al. Lipids in Health and Disease  (2015) 14:9 Page 3 of 16this study were utilized at 80-90% confluence and main-
tained for less than 10 passages.
Lipid emulsions
A soybean oil-based LE that was enriched with omega-6
PUFA (SO; Intralipid®, Fresenius Kabi, Bad Homberg,
Germany), an 80% olive plus 20% soybean LE enriched
with omega-9 MUFA (OO; Clinolipid® or ClinOleic®,
Baxter Healthcare, Deerfield, IL), and a fish oil-based LE
enriched in omega-3 PUFA (FO; Omegaven®, Fresenius
Kabi, Bad Homburg, Germany) were evaluated in the
study (See Table 1). SO and OO were available as 20%
LE (containing 20 g lipid/dl), while FO was available as a
10% LE.
Lipid emulsion (fatty acid) cellular incorporation
Endothelial cells were supplemented with varying
amounts (from 0.1% to 10%) of SO, OO, or FO for
24 hours under standard tissue culture conditions (see
description above). Following treatments, cells were
trypsinized and washed twice in calcium- and
magnesium-free phosphate buffered saline (PBS) con-
taining 0.1% fatty acid-free bovine serum albumin (BSA).
To determine the total cellular fatty acid profile, an in-
ternal standard (C23:0) was added to a known volume of
cell lysate, while protein content was calculated with the
remaining sample using the bicinchoninic acid (BCA)
protein assay kit (R & D Systems, Elysian, MN). Lipids
were extracted using the Folch method, which requires
the use of chloroform:methanol at a 2:1 ratio [19]. Fatty
acid extracts from cell lysates were fractionated into
phospholipid and triglyceride fractions following the
addition of internal standards for each lipid class
(C23:0). These lipid classes were fractionated with thin
layer chromatography (Silica G, 20 x 20, 1000 μm; Ana-
ltech, Newark, DE) using a hexane:diethyl ether:acetic
acid (70:30:1; by volume) solvent system. Phospholipid
and triglyceride bands were collected and subjected to
acid-catalyzed esterification by heating the samples for
90 minutes at 100°C while in a boron trifluoride-
methanol solution (14%). The methyl ester form of the
fatty acids were separated by gas chromatography (Shi-
madzu GC2010; Shimadzu, Columbia, MD) as previ-
ously described [20]. Fatty acid peaks were authenticated
by comparing retention times to standards. Data were
analyzed using Shimadzu’s GC Solutions software and
normalized to protein content. Data were quantified as
either the mean percentage of total identified fatty acids
or as the mean quantity of each fatty acid.
Assessment of lipid droplet formation
HAECs (1 x 104) were plated in 4-well Permanox cham-
ber slides and cultured overnight in complete media. LE
was supplemented (1.0% v/v) for 24 hours under typicaltissue culture conditions. In order to visualize the accu-
mulation of the excess triglycerides, cells were stained
for lipid droplets using an Oil Red O staining kit as de-
scribed by the manufacturer. Modified Mayer’s
hematoxylin was used as a counter-stain to visualize the
cells. Images were obtained using an Olympus BX40 up-
right microscope, at 500x magnification with an oil
immersion objective, and captured with Picture Frame
imaging software.
Apoptosis/necrosis detection
HAECs (1 x 105) were grown in 6-well plates overnight
in EBM-2 complete medium. Endothelial cells were sup-
plemented with varying doses of LE (0.025-0.5%) in fresh
medium for 24 hours under standard tissue culture con-
ditions. Following the treatments, the spent medium
containing any non-adherent cells was collected. The
cells were rinsed in phosphate buffered saline (PBS),
which was also collected, and the adherent cells were
trypsinized and combined with the former material to
ensure that both adherent and non-adherent cells were
harvested for analysis. Cell pellets were washed once in
PBS and resuspended into a labeling solution consisting
of Annexin V FLUOS and propidium iodide. Cell sus-
pensions were maintained at room temperature in the
dark for 20 minutes prior to analysis on a FACSCalibur
flow cytometer (Becton Dickinson, San Jose, CA), which
was equipped with a 15 mW air-cooled argon-ion laser
emitting at a 488 nm wavelength. Annexin V FLUOS
was detected through a 530 nm band pass filter, while
propidium iodide utilized a 630 nm long pass filter. Vi-
able cells do not exhibit labeling by either fluorochrome;
however, apoptotic cells bound the Annexin V FLUOS
and necrotic cells were identified by the presence of
both Annexin V and propidium iodide. Data were quan-
tified using CellQuest software (Becton Dickinson, San
Jose, CA) and represent the mean ± the standard devi-
ation (SD) of three determinations.
HAEC ICAM-1 membrane expression
Endothelial cells were grown in 6-well plates as de-
scribed above. HAECs were supplemented with varying
doses of LE (0.05-0.5%) for 24 hours prior to stimulation
with lipopolysaccharide (LPS, 1 μg/mL) for 4 hours at
37°C to induce an inflammatory reaction. Following cell
stimulation, HAECs were trypsinized, washed in PBS
containing 0.5% BSA, and resuspended in 100 μL of
PBS containing 0.5% BSA and 0.25 μg of phycoery-
thrin (PE)-conjugated intercellular adhesion molecule-1
(ICAM-1) antibody. ICAM-1 labeling occurred at room
temperature in the dark for 20 minutes. Subsequently,
the cells were washed in PBS supplemented with 0.5%
BSA, and cell pellets were resuspended in 300 μL of the
wash buffer and maintained at 4°C in the dark until
Table 1 Fatty acid composition of lipid emulsions (wt % composition)
FA common name/chemical name OO SO FO
6:0 Caproic/Hexanoic acid 0.06 ± 0.002 0.06 ± 0.002 0.14 ± 0.002
8:0 Caprylic/Octanoic acid N/D N/D N/D
10:0 Capric/Decanoic acid N/D N/D N/D
12:0 Lauric/dodecanoic acid N/D N/D 0.05 ± 0.002
14:0 Myristic/Tetradecanoic acid 0.01 ± 0.00 0.05 ± 0.002 4.69 ± 0.05
15:0 Pentadecylic/Pentadecanoic acid N/D N/D 0.36 ± 0.004
16:0 Palmitic/Hexadecanoic acid 13.04 ± 0.14 11.00 ± 0.16 11.62 ± 0.10
16:1n-7 Palmitoleic/Hexadecaenoic acid 0.91 ± 0.013 0.09 ± 0.002 8.05 ± 0.08
16:2n-4 Palmitdienoic/Hexadecadienoic acid N/D N/D 0.94 ± 0.01
17:0 Margaric/Heptadecanoic acid 0.04 ± 0.001 0.07 ± 0.002 0.24 ± 0.01
16:3n-4 Palmittrienoic/hexadecatrienoic acid N/D N/D 0.98 ± 0.01
17:1n-7 Heptadecaenoic 0.07 ± 0.001 0.04 ± 0.002 0.41 ± 0.01
16:4n-1 Palmitotetraenoic/Hexadecatetraenoic acid N/D 0.02 ± 0.002 1.9 ± 0.02
18:0 Stearic/Octadecanoic acid 3.30 ± 0.04 3.90 ± 0.06 2.30 ± 0.02
18:1n-9 Oleic/Octadecaenoic acid 59.69 ± 0.72 20.92 ± 0.30 10.15 ± 0.09
18:1n-7 Vaccenic/Octadecaenoic acid 1.74 ± 0.11 1.29 ± 0.03 2.72 ± 0.02
18:2n-6 Linoleic/Octadecadienoic acid 18.56 ± 0.19 54.68 ± 0.79 2.98 ± 0.02
18:3n-6 γ-Linolenic (GLA)/Octadecatrienoic acid N/D N/D 0.25 ± 0.02
18:3n-3 α-Linolenic (ALA)/Octadecatrienoic acid 1.71 ± 0.02 6.65 ± 0.09 1.23 ± 0.01
18:4n-3 Stearidonic/Octadecatetraenoic acid N/D 0.01 ± 0.00 4.56 ± 0.03
20:0 Arachidic/Eicosanoic acid 0.31 ± 0.004 0.27 ± 0.004 0.05 ± 0.003
20:1n-9 Gondoic/Eicosaenocic acid 0.19 ± 0.003 0.15 ± 0.002 1.10 ± 0.01
20:1n-11 Gadoleic/Eicosaenoic acid N/D 0.03 ± 0.001 0.13 ± 0.01
20:1n-7 Paullinic/Eicosaenoic acid N/D N/D 0.10 ± 0.001
20:2n-6 Eicosadienoic/Eicosdienoic acid N/D 0.01 ± 0.00 0.13 ± 0.01
20:3n-9 Mead acid/Eicosatrienoic acid N/D N/D 0.08 ± 0.01
20:4n-6 Arachidonic (AA)/Eicosatetraenoic acid 0.16 ± 0.002 0.18 ± 0.003 1.47 ± 0.02
20:4n-3 Eicostetraenoic N/D N/D 0.95 ± 0.01
20:5n-3 Timnodonic/Eicosapentaenoic acid (EPA) N/D N/D 19.34 ± 0.20
21:5n-3 Heneicosapentaenoic N/D N/D 0.64 ± 0.01
22:0 Behenic/Docosanoic acid 0.12 ± 0.002 0.31 ± 0.003 0.01 ± 0.001
22:1n-9 Erucic/Docosaenoic acid N/D N/D 0.13 ± 0.01
22:1n-11 Cetoleic/Docosaenoic acid N/D N/D 1.01 ± 0.003
22:4n-6 Adrenic/Docosatetraenoic acid N/D N/D 0.11 ± 0.004
22:5n-6 Osbond/Docosapentaenoic acid (DPA) 0.03 ± 0.003 0.01 ± 0.00 0.40 ± 0.01
22:5n-3 Clupanodonic/Docosapentaenoic acid N/D N/D 1.86 ± 0.02
24:0 Lignoceric/Tetracosanoic acid 0.05 ± 0.00 0.11 ± 0.004 N/D
22:6n-3 Cervonic/Docosahexaenoic acid (DHA) 0.06 ± 0.001 0.11 ± 0.001 17.67 ± 0.17
24:1n-9 Nervonic/Tetracosaenoic acid N/D 0.06 ± 0.08 1.28 ± 1.12
T-SFA 16.62 ± 0.3 15.63 ± 0.28 15.73 ± 0.27
T-MUFA 63.39 ± 1.17 22.77 ± 0.53 23.68 ± 0.53
T-PUFA 20.00 ± 0.40 61.67 ± 1.56 57.54 ± 1.42
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Table 1 Fatty acid composition of lipid emulsions (wt % composition) (Continued)
Omega-3 2.09 ± 0.04 5.66 ± 0.14 54.07 ± 1.28
Omega-6 17.90 ± 0.36 56.01 ± 1.42 3.47 ± 0.14
Total 100.00 ± 1.24 100.00 ± 1.54 100.00 ± 2.12
ND = Not detected.
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each data set to ensure binding specificity. Data analysis
was performed on a FACSCalibur flow cytometer and
CellQuest software as described above; however, the PE
signal was detected through a 585 nm band pass filter.
Results indicate the mean fluorescent intensity of gated
endothelial cells, which exclude cellular debris.
Western blot analysis for phosphorylated NF-kB
Subconfluent HAECs were grown in 6-well tissue
culture-treated plates in the presence or absence of LE
(0.05-0.5%) in EBM-2 complete medium for 24 hours
under standard tissue culture conditions. HAECs were
then stimulated with LPS (1 μg/mL) for 4 hours at 37°C
to mimic an inflammatory insult. Treated cells were
rinsed in cold PBS and lysed on ice for 15 minutes in a
RIPA lysis buffer (10x; Millipore, Temecula, CA) contain-
ing 100 mM NaF, 2 mM Na3VO4, 2.5 mM diisopropyl flu-
orophosphate, and cOmplete mini protease cocktail
inhibitor tablets (Roche Applied Science, Indianapolis,
IN). A BCA protein assay kit was used to determine the
protein content following sample centrifugation to remove
the insoluble matter from the detergent solubilized ex-
tracts. Linearized proteins were electrophoretically
separated in 4-12% polyacrylamide gradient gels and
transferred onto nitrocellulose membranes. Membranes
were blocked for 30 minutes at room temperature in 10%
Roche western blocking reagent in Tris-buffered saline
supplemented with 0.1% Triton X-100 (TBST). Blots were
probed with primary antibodies in accordance with the
manufacturer’s recommendations. Secondary antibodies
were peroxidase-conjugated for protein detection using an
enhanced chemiluminescence (ECL) system (Amersham
Pharmacia Biotechnology, Piscataway, NJ). Nitrocellulose
membranes were stripped in Restore western blot strip-
ping buffer (Thermo Scientific, Rockford, IL) for 15 mi-
nutes at room temperature. Stripped blots were washed 6
times in TBST, blocked, and reprobed with an alternative
antibody.
Statistical analysis
Data represent the mean ± the standard deviation (SD)
of at least three determinations. Student’s t-test was used
to signify statistically significant differences between
treatment groups and vehicle control. One-way ANOVA
with Tukey’s post hoc test using SPSS Statistics 20 soft-
ware was performed to test differences between groups.When a calculated p value of <0.05 is reported, statistical
significance is indicated with an asterisk.
Results
Lipid emulsion cellular incorporation
HAECs were dose dependently supplemented with lipid
emulsions (0.1-10%). Separate vehicle (PBS-supple-
mented) cells were used with each emulsion. Incorpor-
ation of total fatty acids in HAECs varied with different
lipid emulsions, as shown in Figure 1. The total fatty
acid uptake was lowest in SO-based LE, whereas it was
highest in OO-based lipid emulsion (2–2.5 fold higher
compared to SO). Supplementation with FO-based LE
demonstrated an intermediate increase in total fatty acid
uptake. The relative percentages of key identified fatty
acids in total lipid extracts from the endothelial cells are
presented in Tables 2, 3 and 4.
In the vehicle (PBS-supplemented) cells, the saturated
fatty acid class represented nearly one-half of all selected
fatty acids (Tables 2, 3 and 4). MUFA were the second
most abundant class of fatty acids, followed by n-6
PUFA and n-3 PUFA. As the percentage of OO supple-
mentation increased (Table 2), the proportion of oleic
and linoleic acid, and to a lesser extent α- and γ-
linolenic acids and docosahexaenoic acid, increased in
a dose-dependent manner. Palmitic and arachidonic
acids maintained a consistent presence independent of
lipid emulsion supplementation; furthermore, relative
levels of myristic acid and the MUFAs, palmitoleic and
vaccenic, declined. SO-supplemented endothelial cells
(Table 3) demonstrated dose-dependent increases in
the relative percentages of linoleic and γ-linolenic
acids. The saturated fatty acids, with the exception of
palmitic, displayed dose-dependent decreases. The
percentage of oleic acid content was unchanged but
levels of total MUFA were decreased. The FO-
supplemented endothelial cells were administered the
same volume/volume dose as OO and SO. However,
the lipid concentration of FO was 10% compared to
20% in the OO and SO emulsions. Dose-dependent
increases in the proportion of DHA and EPA were
observed (Table 4) with the FO emulsion; however, the
relative percentages of docosapentaenoic acid and α-
linolenic acid did not substantially increase. The satu-
rated fatty acid component decreased, whereas a
significant increase in the percentage of oleic and lino-
leic acids was observed.
Lipid Emulsion ( % V/V)
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Figure 1 Concentration of total fatty acids in endothelial cells following lipid emulsion supplementation. Cells were supplemented with
varying amounts of olive oil (OO)-, soybean oil (SO)-, or fish oil (FO)-based lipid emulsion. The amounts of total fatty acids were determined as
the sum of all detectable fatty acids reported in Table 1. Each point represents the mean ± SD of three determinations.
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As shown in Figure 1, the overall cellular fatty acid con-
tent increased following LE supplementation in a dose-
dependent manner. Thus, we determined whether the
fatty acids were incorporated into cellular triglyceride
(TG) and/or phospholipid (PL) fractions (Table 5).
Minimal amounts of triglycerides were detected in non-
supplemented endothelial cells, which resulted in many
non-detectable fatty acids; however, significant levels
were detected in all LE-supplemented cells (Table 5a).
The fatty acid incorporation in TG mimicked the fatty
acid profiles present in the lipid emulsions. However, the
amount of fatty acid incorporated into TG and PL frac-
tions varied with different LEs. In untreated HAECs,
95% of total fatty acids were present in the PL fraction
and 5% in the TG fraction. Following OO-based LE sup-
plementation, fatty acids were equally distributed in TG
(51%) and PL (49%) fractions, whereas in SO-based LE
supplementation, 36% and 64% of total fatty acids were
present in the TG and PL fractions, respectively. In the
FO-supplemented cells, more fatty acids were incorpo-
rated into the TG fraction (61%) with lesser amounts in
the PL fraction (39%). The long-chain saturated fatty
acids (>20 carbon chain length) were not detected in any
of the triglyceride fractions.
Oil Red O staining, which detects neutral cellular
lipids in the form of lipid droplets, was used to confirm
the triglyceride accumulation in the LE-supplemented
endothelial cells (Figure 2). Lipid droplets were virtuallyundetected in non-supplemented endothelial cells. SO-
supplemented cells consistently generated smaller lipid
droplets compared to the much larger lipid droplets
present in the OO- and FO-supplemented endothelial
cells. Larger lipid droplets were consistent with the
higher triglyceride levels in cells supplemented with OO
(51%) or FO (61%) (Table 5a).
Effect of lipid emulsion supplementation on HAEC
apoptosis/necrosis
Endothelial cell viability was assessed after exposure of
the cells to 0–0.5% v/v of LE. Cells were subsequently
classified as viable, apoptotic, or necrotic (Table 6). OO
supplementation of the endothelial cells improved cell
viability. No statistically significant differences were
observed within any cell classification in the SO-
supplemented endothelial cells. FO supplementation of
the cells decreased viability, demonstrating increases
in both apoptosis and necrosis.
Effect of lipid emulsion supplementation on
lipopolysaccharide-induced ICAM-1 surface expression
LPS-induced surface expression of ICAM-1 is utilized
as a method to assess a proinflammatory response in
endothelial cells; therefore, we used this method to
determine if endothelial cells pretreated with LE were
capable of modulating the LPS-induced inflammatory
response. LPS-induced ICAM-1 expression increased
nearly five-fold over levels in non-stimulated endothelial
Table 2 Fatty acid profile in OO-supplemented HAECs
Fatty acid Vehicle 0.10% 1% 2% 5% 10%
8:0 0.76 ± 0.21 0.24 ± 0.03* 0.10 ± 0.00* 0.12 ± 0.01* 0.12 ± 0.04* 0.06 ± 0.05*
10:0 0.52 ± 0.35 0.25 ± 0.00 0.06 ± 0.00 0.14 ± 0.03* 0.10 ± 0.02* 0.14 ± 0.05*
12:0 0.19 ± 0.10 0.19 ± 0.10 0.11 ± 0.02 0.07 ± 0.02 0.04 ± 0.00* 0.08 ± 0.05
14:0 3.51 ± 0.41 3.02 ± 0.27 1.03 ± 0.15* 0.71 ± 0.11* 0.60 ± 0.04* 0.53 ± 0.00*
16:0 26.37 ± 2.33 25.09 ± 1.81 27.39 ± 1.71 24.32 ± 2.25 25.09 ± 1.11 25.33 ± 1.39
16:1n-7 4.31 ± 0.01 3.05 ± 0.18* 1.39 ± 0.04* 1.51 ± 0.11* 1.45 ± 0.03* 1.39 ± 0.10*
18:0 16.50 ± 2.01 17.27 ± 1.98 10.89 ± 0.96 11.69 ± 1.24* 9.96 ± 0.14* 8.35 ± 0.40*
18:1n-9 20.94 ± 0.76 23.31 ± 2.13 30.97 ± 1.73* 33.23 ± 3.44* 32.27 ± 0.53* 31.15 ± 2.01*
18:1n-7 8.13 ± 0.03 7.59 ± 0.12* 2.74 ± 0.18* 3.90 ± 0.63* 3.07 ± 0.22* 2.64 ± 0.19*
18:2n-6 1.50 ± 0.16 2.12 ± 0.13 10.26 ± 0.66* 11.08 ± 0.86* 13.63 ± 0.59* 15.81 ± 0.91*
18:3n-6 0.16 ± 0.02 0.19 ± 0.05 1.30 ± 0.11* 0.50 ± 0.07* 0.73 ± 0.01* 0.73 ± 0.09*
18:3n-3 0.05 ± 0.01 0.05 ± 0.03 0.04 ± 0.01 0.19 ± 0.01* 0.25 ± 0.00* 0.35 ± 0.02*
20:0 0.17 ± 0.02 0.14 ± 0.03 0.05 ± 0.01 0.15 ± 0.00 0.13 ± 0.00* 0.11 ± 0.00*
20:4n-6 10.78 ± 0.18 11.29 ± 0.47 8.77 ± 0.46 7.83 ± 0.79* 8.01 ± 0.67* 8.90 ± 0.40*
20:5n-3 0.19 ± 0.00 0.20 ± 0.04 0.06 ± 0.00* 0.11 ± 0.02* 0.10 ± 0.02* 0.09 ± 0.01*
22:0 0.23 ± 0.02 0.19 ± 0.02 0.19 ± 0.06 0.12 ± 0.02* 0.08 ± 0.00* 0.05 ± 0.00*
22:5n-6 1.62 ± 0.02 1.75 ± 0.05 1.16 ± 0.05* 1.11 ± 0.06* 1.19 ± 0.11* 1.20 ± 0.07*
22:5n-3 1.57 ± 0.04 1.56 ± 0.16 0.55 ± 0.03* 0.67 ± 0.03* 0.52 ± 0.03* 0.45 ± 0.03*
24:0 0.47 ± 0.01 0.38 ± 0.04 0.07 ± 0.00 0.13 ± 0.01* 0.09 ± 0.00* 0.07 ± 0.00*
22:6n-3 2.03 ± 0.09 2.14 ± 0.00 2.88 ± 0.15* 2.42 ± 0.13* 2.57 ± 0.09* 2.57 ± 0.15*
SFA 48.72 ± 5.97 46.75 ± 4.29 39.89 ± 2.91* 37.45 ± 3.69* 36.21 ± 1.36* 34.74 ± 1.95*
MUFA 33.39 ± 0.80 33.95 ± 2.43 35.09 ± 1.95 38.64 ± 4.18 36.80 ± 0.77 35.17 ± 2.29
n-6 PUFA 14.06 ± 0.38 15.35 ± 0.69 20.23 ± 1.18* 20.52 ± 1.77* 23.56 ± 1.38* 26.64 ± 1.47*
n-3 PUFA 3.84 ± 0.14 3.95 ± 0.23 4.79 ± 0.29* 3.39 ± 0.18 3.44 ± 0.14 3.45 ± 0.21
Total 100 ± 7.28 100.00 ± 7.63 100.00 ± 6.33 100.00 ± 9.84 100.00 ± 3.66 100.00 ± 5.92
HAECs were supplemented with varying doses of OO for 24 hours under standard tissue culture conditions prior to analysis. Total lipids were extracted as
described in the methods. Quantification was based on the use of an internal standard and normalization to protein content. Results are expressed as the mean
wt% ± SD of three determinants. *Denotes statistically significant differences (p ≤ 0.05) compared to vehicle control.
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ICAM-1 expression were observed in OO-supplemented
cells, but the highest amount of OO (0.5% v/v) was
only able to suppress the LPS-induced response by
roughly one-half. In the SO- supplemented cells,
ICAM-1 expression was decreased at the higher but
not the lower doses of the emulsion. LPS-induced
ICAM-1 expression was significantly inhibited follow-
ing all doses of FO. Both the 0.25% and 0.5% FO emul-
sion doses completely inhibited ICAM-1 expression in
the cells. To ensure that the LE were not directly inter-
fering with the LPS stimulating effect, ICAM-1 expres-
sion levels were also quantified in cells that underwent
two washes to remove residual LE prior to LPS stimu-
lation, and results were compared with the unwashed
cells. No significant differences existed between the re-
peatedly washed samples and the unwashed cells (data
not shown).Effect of lipid emulsion supplementation on NF-kΒ
phosphorylation
ICAM-1 expression is stimulated by activation (phos-
phorylation) of the transcription factor NF-κB. Thus, to
determine if the anti-inflammatory properties (suppres-
sion of ICAM-1 expression) of the LEs were linked to
suppression of NF-κB phosphorylation, we measured
this molecule in both unstimulated and LPS-stimulated
cells before and following exposure to the LE (0.05-
0.5% v/v). In Figure 4A, LPS-stimulated endothelial cells
demonstrated elevated expression of phosphorylated
NF-κB regardless of whether cells were pretreated with
OO, which was administered at levels previously shown
to significantly inhibit ICAM-1 surface expression. OO
supplementation did not appear to alter baseline NF-κB
phosphorylation. SO supplementation partially lowered
baseline NF-κB phosphorylation; however, the LPS-induced
phosphorylation was not altered by the SO pretreatment
Table 3 Fatty acid profile in SO-supplemented HAECs
Fatty acid Vehicle 0.10% 1% 2% 5% 10%
8:0 0.41 ± 0.16 0.25 ± 0.07* 0.25 ± 0.05 0.28 ± 0.00 0.17 ± 0.02* 0.11 ± 0.00*
10:0 0.62 ± 0.28 0.43 ± 0.08 0.14 ± 0.01 0.48 ± 0.08 0.32 ± 0.01* 0.19 ± 0.05*
12:0 0.16 ± 0.05 0.19 ± 0.09 0.27 ± 0.04 0.24 ± 0.16 0.17 ± 0.01 0.11 ± 0.02
14:0 4.08 ± 0.85 3.75 ± 0.04 1.24 ± 0.06* 1.40 ± 0.08* 1.01 ± 0.04* 0.74 ± 0.10*
16:0 25.99 ± 4.34 25.07 ± 0.37 26.03 ± 1.38 24.05 ± 2.75 24.29 ± 0.32 24.30 ± 0.88
16:1n-7 4.16 ± 0.47 3.84 ± 0.04 1.05 ± 0.07* 1.96 ± 0.14* 1.55 ± 0.02* 1.49 ± 0.11*
18:0 16.94 ± 2.65 17.28 ± 0.25 13.89 ± 0.65 17.01 ± 1.76 15.34 ± 0.13 12.75 ± 0.69
18:1n-9 21.04 ± 3.08 20.60 ± 0.51 20.73 ± 1.11 20.64 ± 2.91 20.55 ± 0.22 20.13 ± 0.83
18:1n-7 8.34 ± 1.39 8.06 ± 0.18 2.43 ± 0.13* 4.23 ± 0.56* 3.43 ± 0.00* 2.59 ± 0.05*
18:2n-6 1.57 ± 0.24 2.08 ± 0.05 14.21 ± 0.85* 10.28 ± 1.97* 12.41 ± 0.75* 15.43 ± 0.52*
18:3n-6 0.16 ± 0.07 0.15 ± 0.01 0.82 ± 0.05* 0.44 ± 0.10* 0.68 ± 0.12* 1.12 ± 0.00*
18:3n-3 0.02 ± 0.01 0.01 ± 0.01 0.37 ± 0.03* 0.39 ± 0.09* 0.36 ± 0.00* 0.40 ± 0.02*
20:0 0.23 ± 0.04 0.20 ± 0.00 0.05 ± 0.01 0.25 ± 0.00 0.21 ± 0.01 0.17 ± 0.02
20:4n-6 10.22 ± 2.01 11.40 ± 0.25 10.81 ± 0.66 11.51 ± 1.36 11.96 ± 0.08 12.61 ± 0.37
20:5n-3 0.20 ± 0.04 0.20 ± 0.00 0.29 ± 0.03 0.16 ± 0.04 0.20 ± 0.02 0.24 ± 0.01
22:0 0.26 ± 0.05 0.22 ± 0.00 0.12 ± 0.01 0.22 ± 0.02 0.18 ± 0.01 0.14 ± 0.01*
22:5n-6 1.52 ± 0.38 1.78 ± 0.03 0.94 ± 0.04 1.19 ± 0.21 1.24 ± 0.02 1.22 ± 0.06
22:5n-3 1.62 ± 0.17 1.66 ± 0.09 1.06 ± 0.07 1.31 ± 0.24 1.10 ± 0.02* 0.84 ± 0.00*
24:0 0.43 ± 0.15 0.35 ± 0.02 0.12 ± 0.01 0.23 ± 0.06* 0.14 ± 0.02* 0.13 ± 0.01*
22:6n-3 1.91 ± 0.29 2.34 ± 0.06 5.18 ± 0.31* 4.05 ± 0.65* 4.98 ± 0.32* 5.68 ± 0.14*
SFA 49.11 ± 8.58 47.74 ± 0.94 42.11 ± 2.22 44.17 ± 4.91 41.85 ± 0.59 38.62 ± 1.77
MUFA 33.54 ± 4.93 32.50 ± 0.72 24.20 ± 1.31* 26.83 ± 3.61* 25.53 ± 0.25* 24.21 ± 0.99*
n-6 PUFA 13.46 ± 2.71 15.41 ± 0.33 26.33 ± 1.59* 23.42 ± 3.64* 26.30 ± 0.98* 30.38 ± 0.95*
n-3 PUFA 3.76 ± 0.50 4.22 ± 0.17 7.36 ± 0.45* 5.91 ± 1.02 6.63 ± 0.36 7.16 ± 0.18*
Total 99.87 ± 16.73 99.87 ± 2.17 100.00 ± 5.57 100.33 ± 13.18* 100.31 ± 2.18* 100.36 ± 3.89
HAECs were supplemented with varying doses of SO for 24 hours under standard tissue culture conditions prior to analysis. Total lipids were extracted as
described in the methods. Quantification was based on the use of an internal standard and normalization to protein content. Results are expressed as the mean
wt% ± SD of three determinants. *Denotes statistically significant differences (p ≤ 0.05) compared to vehicle control.
Harvey et al. Lipids in Health and Disease  (2015) 14:9 Page 8 of 16(Figure 4B). FO supplementation did not affect baseline
NF-κB phosphorylation. However, FO exposure decreased
LPS-induced NF-κB phosphorylation (Figure 4C). Inter-
estingly, all three LEs were capable of inhibiting ICAM-1
surface expression; however, only FO supplemented endo-
thelial cells demonstrated decreased ICAM-1 expression
and NF-κB phosphorylation.
Discussion
Patients receiving parenteral nutrition frequently suffer
from intravenous thrombosis and dysfunctional immune
systems as a result of underlying disease (including pro-
inflammatory insults), endothelial cell damage, disrup-
tion of the gastrointestinal-immune axis, malnutrition,
and nutrient deficiencies/excesses. Loss of endothelial
cell integrity (necrosis and apoptosis) predisposes to
thrombosis by disrupting endothelial anticoagulant
activities as well as contributing to the activation of co-
agulation. Dysregulation of immune and inflammatoryresponses during parenteral nutrition contributes to in-
fections and/or tissue damage and organ failure.
Despite the importance of endothelial cells in the pre-
vention of thrombosis and support of immune/inflam-
matory responses, few previous studies have evaluated
the effects of LEs upon these endothelial cell functions.
Thus, in this study we evaluated the effects of three
major classes of commercial LEs. We were particularly
interested in evaluating the pro-inflammatory versus
anti-inflammatory potential of the three LEs upon endo-
thelial cell integrity and function. Our results indicate
that the n-6 predominant, n-3 predominant, and n-9
predominant LEs all suppress inflammatory endothelial
cell activation. However, the dose–response effect indi-
cates a difference in potency with the n-3 PUFA > n-9
MUFA > n-6 PUFA predominant LE. We found no evi-
dence that any of the LEs increased the LPS-induced
ICAM-1 response. Interestingly, we found that the fish
oil emulsion increased both endothelial cell apoptosis
Table 4 Fatty acid profile in FO-supplemented HAECs
Fatty acid Vehicle 0.10% 1% 2% 5% 10%
8:0 0.18 ± 0.04 0.25 ± 0.03 0.52 ± 0.11* 0.20 ± 0.03 0.20 ± 0.03 0.08 ± 0.03*
10:0 0.24 ± 0.09 0.26 ± 0.06 0.46 ± 0.05* 0.15 ± 0.03 0.18 ± 0.08 0.11 ± 0.05
12:0 0.18 ± 0.02 0.13 ± 0.00* 0.31 ± 0.06* 0.14 ± 0.01 0.14 ± 0.09 0.06 ± 0.02*
14:0 3.61 ± 0.18 4.27 ± 0.79 3.96 ± 1.06 5.35 ± 0.20* 1.47 ± 0.10* 1.05 ± 0.06*
16:0 26.56 ± 1.37 22.37 ± 3.35 21.85 ± 1.87* 22.85 ± 1.10* 19.26 ± 2.26* 20.23 ± 1.40*
16:1n-7 4.86 ± 0.31 5.69 ± 1.48 4.98 ± 1.74 7.28 ± 0.10* 2.36 ± 0.35* 1.84 ± 0.07*
18:0 16.90 ± 1.29 16.63 ± 2.07 15.39 ± 0.20 7.87 ± 0.48* 12.21 ± 1.18* 8.82 ± 0.31*
18:1n-9 21.97 ± 1.29 21.35 ± 3.63 25.59 ± 0.46* 25.58 ± 1.74 35.53 ± 4.81* 39.75 ± 1.89*
18:1n-7 8.47 ± 0.72 8.82 ± 1.62 4.78 ± 0.84* 4.25 ± 0.10* 3.44 ± 0.26* 2.81 ± 0.00*
18:2n-6 1.13 ± 0.13 2.63 ± 0.73 3.81 ± 0.26* 6.78 ± 0.46* 6.55 ± 0.89* 8.39 ± 0.45*
18:3n-6 0.13 ± 0.01 0.13 ± 0.01 0.25 ± 0.03* 0.27 ± 0.02* 0.30 ± 0.04* 0.31 ± 0.01*
18:3n-3 0.03 ± 0.02 0.17 ± 0.06* 0.26 ± 0.15 0.59 ± 0.02* 0.06 ± 0.04 0.13 ± 0.00*
20:0 0.26 ± 0.04 0.31 ± 0.04 0.42 ± 0.08* 0.20 ± 0.01 0.25 ± 0.02 0.13 ± 0.01*
20:4n-6 9.85 ± 0.53 9.37 ± 1.29 7.41 ± 0.30* 8.51 ± 0.39 8.31 ± 0.81 7.48 ± 0.27*
20:5n-3 0.21 ± 0.03 0.77 ± 0.24* 2.83 ± 0.59* 2.87 ± 0.16* 1.77 ± 0.09* 1.87 ± 0.08*
22:0 0.28 ± 0.01 0.27 ± 0.04 0.31 ± 0.00 0.12 ± 0.01* 0.16 ± 0.01* 0.07 ± 0.01*
22:5n-6 1.47 ± 0.07 1.29 ± 0.19 0.97 ± 0.03* 0.79 ± 0.07* 1.27 ± 0.11 1.14 ± 0.00*
22:5n-3 1.42 ± 0.05 2.46 ± 0.40* 1.46 ± 0.01 1.20 ± 0.12 1.78 ± 0.23 1.53 ± 0.03
24:0 0.35 ± 0.00 0.37 ± 0.02 0.47 ± 0.03* 0.11 ± 0.01* 0.20 ± 0.03* 0.07 ± 0.01*
22:6n-3 1.90 ± 0.06 2.47 ± 0.48 3.97 ± 0.20* 4.89 ± 0.29* 4.55 ± 0.61* 4.12 ± 0.02*
SFA 48.55 ± 3.05 44.85 ± 6.60 43.68 ± 3.46 36.98 ± 1.88* 34.08 ± 3.80* 30.63 ± 1.91*
MUFA 35.30 ± 2.32 35.86 ± 6.73 35.36 ± 3.04 37.11 ± 1.94 41.32 ± 5.41 44.41 ± 1.95*
n-6 PUFA 12.59 ± 0.74 13.42 ± 2.22 12.44 ± 0.61 16.27 ± 0.93* 16.43 ± 1.85* 17.32 ± 0.73*
n-3 PUFA 3.56 ± 0.16 5.86 ± 1.18* 8.52 ± 0.95* 9.63 ± 0.60* 8.16 ± 0.98* 7.64 ± 0.13*
Total 100.00 ± 6.27 100.00 ± 16.74 100.00 ± 8.07 100.00 ± 5.34 100.00 ± 12.04 100.00 ± 4.72
HAECs were supplemented with varying doses of FO for 24 hours under standard tissue culture conditions prior to analysis. Total lipids were extracted as
described in the methods. Quantification was based on the use of an internal standard and normalization to protein content. Results are expressed as the mean
wt% ± SD of three determinants. *Denotes statistically significant differences (p ≤ 0.05) compared to vehicle control.
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upon these endothelial parameters, and the olive oil-
predominant emulsion decreased necrosis without alter-
ing apoptosis.
LE effects upon endothelial cells primarily result from
their uptake and incorporation into cell membranes and
cytoplasmic compartments, where they modulate cell
membrane structure-function, generation of cell signal-
ing molecules (such as second messengers and transcrip-
tion factors), and alter gene transcription. Our results
indicate that all three LE were readily incorporated into
endothelial cells in a dose-dependent manner (Tables 2,
3, 4 and Figure 1). The fatty acid profiles within the
endothelial cells generally reflected the composition of
the emulsions (Tables 1, 2, 3 and 4). Interestingly, we
also found that the amount of fatty acid incorporated
into endothelial cells varied among the different LEs.
Significantly greater fatty acid was incorporated using
the OO compared to the SO and FO emulsions(Figure 1). The FO emulsion was a 10% LE compared to
the 20% LEs used for OO and SO. However, even when
adjusted for the concentration of fatty acid administered,
the OO emulsion was incorporated at higher levels than
the other emulsions. When adjusted for fatty acid dose
administered, the FO emulsion was incorporated at
higher levels than the SO emulsion.
The phospholipid fraction within endothelial cells
represents fatty acid content within cell surface and or-
ganelle membranes, while the triglyceride content rep-
resents cytoplasmic lipid or lipid within vesicles (such
as pinocytotic vesicles or peroxisomes). Increases in
fatty acids occurred in both the triglyceride and
phospholipid fractions of the cell. Non-supplemented
endothelial cells possessed a relatively small amount of
triglycerides (4.5% of total fatty), whereas the percentages
of triglyceride content were significantly elevated in OO
(51.14%), SO (36.14%), and FO (60.6%) supplemented
endothelial cells. Increased cellular lipid uptake from the
Table 5 Analysis of FA in triglyceride and phospholipid fractions
(a) Triglyceride (b) Phospholipid
Fatty acid Vehicle OO SO FO Fatty acid Vehicle OO SO FO
C8:0 0.14 ± 0.05a 0.06 ± 0.00b 0.15 ± 0.08a 0.10 ± 0.04a C8:0 0.13 ± 0.04a 0.04 ± 0.00b 0.11 ± 0.03a 0.16 ± 0.05a
C10:0 0.05 ± 0.01a 0.03 ± 0.01a 0.09 ± 0.01a 0.06 ± 0.03a C10:0 0.07 ± 0.01a 0.03 ± 0.00a 0.05 ± 0.01a 0.10 ± 0.05a
C12:0 0.14 ± 0.02a 0.07 ± 0.02b 0.21 ± 0.08a 0.03 ± 0.01b C12:0 0.15 ± 0.06a 0.04 ± 0.01b 0.06 ± 0.00b 0.05 ± 0.04b
C14:0 0.42 ± 0.04a 0.41 ± 0.05a 0.42 ± 0.02a 0.81 ± 0.07b C14:0 3.36 ± 0.30a 0.62 ± 0.25b 0.82 ± 0.10b 0.92 ± 0.37b
C16:0 1.19 ± 0.42a 12.98 ± 1.67b 8.06 ± 0.92c 12.92 ± 1.74b C16:0 25.93 ± 1.65a 14.41 ± 1.74b 17.97 ± 1.83b 11.15 ± 1.60b
C16:1n7 0.17 ± 0.06a 0.67 ± 0.07b 0.33 ± 0.03c 0.48 ± 0.08d C16:1n7 3.69 ± 0.20a 0.72 ± 0.02b 0.72 ± 0.10b 0.43 ± 0.05c
C18:0 0.54 ± 0.15a 3.47 ± 0.42b 2.97 ± 0.30b 3.24 ± 0.39b C18:0 15.79 ± 0.70a 7.43 ± 1.51b 10.93 ± 1.01b 5.99 ± 1.40b
C18:1n-9 0.85 ± 0.32a 19.41 ± 2.31b 8.50 ± 0.91c 22.12 ± 3.65b C18:1n-9 20.82 ± 1.09a 11.56 ± 1.14b 12.22 ± 1.30b 10.26 ± 2.78b
C18:1 n-7 0.19 ± 0.07a 1.05 ± 0.24b 0.51 ± 0.06c 1.17 ± 0.17b C18:1 n-7 8.16 ± 0.40a 1.69 ± 0.12b 1.92 ± 0.21b 1.21 ± 0.18b
C18:2n-6 0.70 ± 0.99a 6.07 ± 0.82b 7.54 ± 1.01b 7.53 ± 1.31b C18:2n-6 1.39 ± 0.05a 4.19 ± 0.51b 6.66 ± 0.69c 2.98 ± 0.54b
C18:3n-3 N/D 0.98 ± 0.17a 0.51 ± 0.06b 0.17 ± 0.03c C18:3n-3 0.15 ± 0.02a 0.32 ± 0.04b 0.31 ± 0.04b 0.11 ± 0.03a
C18:3n-6 N/D N/D 0.29 ± 0.05a 0.08 ± 0.01b C18:3n-6 0.05 ± 0.02a 0.04 ± 0.01a 0.08 ± 0.02a 0.03 ± 0.01a
C20:0 N/D N/D N/D N/D C20:0 0.10 ± 0.00a 0.05 ± 0.02b 0.05 ± 0.02b 0.06 ± 0.02b
C20:4n-6 N/D 4.02 ± 0.49a 3.80 ± 0.51a 4.96 ± 0.76a C20:4n-6 9.74 ± 0.16a 4.75 ± 0.43b 7.00 ± 0.82c 3.54 ± 0.59b
C20:5n-3 N/D N/D 0.15 ± 0.02a 2.45 ± 0.40b C20:5n-3 0.12 ± 0.01a 0.06 ± 0.01b 0.14 ± 0.04a 0.66 ± 0.09c
C22:0 0.13 ± 0.02 N/D N/D N/D C22:0 0.22 ± 0.03a 0.19 ± 0.13a 0.12 ± 0.02b 0.11 ± 0.02b
C22:5n-6 N/D 0.45 ± 0.07a 0.25 ± 0.01b 0.78 ± 0.15a C22:5n-6 1.28 ± 0.03a 0.71 ± 0.04b 0.70 ± 0.08b 0.44 ± 0.06c
C22:5n-3 N/D 0.20 ± 0.03a 0.35 ± 0.05b 0.82 ± 0.32c C22:5n-3 1.62 ± 0.04a 0.35 ± 0.02b 0.71 ± 0.09c 0.32 ± 0.06b
C24:0 N/D N/D N/D N/D C24:0 0.30 ± 0.03a 0.07 ± 0.01b 0.12 ± 0.01c 0.08 ± 0.01b
C22:6n-3 N/D 1.28 ± 0.17a 2.00 ± 0.31a,b 2.82 ± 0.54b,c C22:6n-3 2.26 ± 0.07a 1.60 ± 0.14b 3.18 ± 0.31a 0.84 ± 0.24c
SFA 2.60 ± 0.72a 17.01 ± 2.17b 11.90 ± 1.41c 17.16 ± 2.27b SFA 46.05 ± 2.82a 22.88 ± 3.66b 30.21 ± 3.04c 18.64 ± 3.57b
MUFA 1.21 ± 0.46a 21.13 ± 2.62b 9.34 ± 1.00c 23.77 ± 3.90b MUFA 32.67 ± 1.69a 13.9 ± 61.28b 14.86 ± 1.61b 11.90 ± 3.01b
n-6 PUFA 0.70 ± 0.99a 10.55 ± 1.39b 11.88 ± 1.57b 13.35 ± 2.24b n-6 PUFA 12.45 ± 0.25a 9.68 ± 0.98b 14.44 ± 1.60a 6.99 ± 1.20c
n-3 PUFA N/D 2.45 ± 0.37a 3.01 ± 0.43a 6.27 ± 1.28b n-3 PUFA 4.15 ± 0.15a 2.33 ± 0.20b 4.35 ± 0.47a 1.92 ± 0.42b
TOTAL 4.52 ± 2.18a 51.14 ± 6.54b 36.14 ± 4.42c 60.55 ± 9.69b TOTAL 95.32 ± 4.91a 48.86 ± 6.12b 63.86 ± 6.72c 39.45 ± 8.20b
HAECs were supplemented with lipid emulsions (1%) for 24 hours under standard tissue culture conditions prior to analysis. Triglycerides (a) and Phospholipids (b)
were resolved using thin layer chromatography and extracted as described in the methods. An “ND” indicates the lack of fatty acid detection. Results are
expressed as the mean (wt%) ± SD of three experiments. One-way ANOVA with Tukey’s post hoc test using SPSS Statistics 20 software was performed to test
differences between groups. The numbers with different letters represent a statistically significant difference p < 0.05.
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namely triglycerides, as demonstrated by red oil O stain-
ing. Interestingly, SO was associated with numerous small
droplets, while OO and FO were characterized by fewer
but larger droplets. The larger droplets were consistent
with higher cellular triglyceride content. From our pre-
vious study [8], we found that these intracellular lipid
droplets disappear over time when the lipid emulsion is
removed from the cells indicating that the lipid can be
metabolized. The difference in speed of cellular uptake/
incorporation, and the size and number of the droplets
suggests that there is a difference in cellular lipid pro-
cessing between the different emulsions. The mecha-
nisms for this difference and potential physiologic
effects requires further study. It is clear from these
in vitro studies that fatty acid content of endothelial
cells is modulated by the fatty acid content of the LE.Apoptosis/necrosis of cells may play a role is endothelial
dysfunction during acute (i.e. sepsis, vascular permeability,
thrombosis) and chronic diseases (ie. atherosclerosis, nutri-
ent and oxygen transport into tissues) [7,21,22]. Endothelial
cell apoptosis may increase vascular thrombogenicity by an
alteration of membrane phospholipid structure, loss of
endothelial anti-coagulant proteins, enhanced binding and
activation of coagulant factors, and/or exposure of the
underlying procoagulant subcellular matrix [21,22]. Loss of
endothelial nitric oxide production and endothelial nitric
oxide synthase activity may also lead to a procoagulant state
[6]. Thrombosis is an important complication associated
with administration of parenteral nutrition and the effects
of lipids upon thrombogenicity represents an important
area for study.
Nonesterified free fatty acids have been reported to in-
duce apoptosis in endothelial cells [5-9]. Free fatty acids
Figure 2 Effect of lipid emulsion supplementation on the accumulation of neutral lipid storage. Endothelial cells (PBS, A) were cultured
for 24 hours in the presence of 1% (v/v) OO (B), SO (C), or FO (D). Triglyceride-containing lipid droplets were stained with Oil Red O, while cells
were counterstained with hematoxylin for visualization.
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dants [6,7] and activation of NF-κB [5-9]. The apoptosis-
inducing effects of free fatty acids differ among different
fatty acids. Some investigators have reported induction
of apoptosis with saturated free fatty acids but not un-
saturated free fatty acids [5,6,8]. In addition, mixingTable 6 Effect of lipid emulsion supplementation on
endothelial cell apoptosis/necrosis
Apoptosis/necrosis detection (mean ± SD)
% (v/v) Viable Apoptotic Necrotic
Vehicle 82.9 ± 1.9 6.2 ± 1.8 10.9 ± 1.9
OO 0.5 86.8 ± 1.3* 6.0 ± 0.6 7.2 ± 1.0*
0.1 87.7 ± 0.4* 5.9 ± 0.2 6.5 ± 0.3*
0.05 84.7 ± 2.0 6.8 ± 1.0 8.5 ± 1.0
0.025 84.5 ± 0.1 7.2 ± 0.8 7.9 ± 1.0
SO 0.5 81.6 ± 0.6 4.7 ± 1.2 13.8 ± 1.6
0.1 85.6 ± 1.3 5.7 ± 0.9 8.7 ± 1.9
0.05 84.1 ± 2.2 4.6 ± 0.5 11.3 ± 2.3
0.025 82.7 ± 2.5 3.7 ± 0.9 12.9 ± 1.8
FO 0.5 64.2 ± 3.1* 12.9 ± 2.1* 22.9 ± 1.3*
0.1 63.8 ± 2.0* 10.1 ± 3.3* 26.1 ± 4.6*
0.05 76.8 ± 1.5* 6.9 ± 0.6 16.4 ± 1.4*
0.025 79.9 ± 1.7 6.7 ± 0.7 13.4 ± 1.2
HAECs were supplemented with varying doses of lipid emulsions for 24 hours
under standard tissue culture conditions. Cells were harvested and labeled
with Annexin V FLUOS and propidium iodide as described in the methods.
Results are expressed as the mean ± SD of three experiments. *Denotes
statistical differences (p ≤ 0.05) within each cell classification compared to
vehicle control.unsaturated free fatty acids with saturated free fatty
acids inhibited induction of apoptosis [5,6,8]. Thus,
there appear to be interactions among different fatty
acids, which can modulate their cellular actions. Lipid
emulsions are emulsified complex mixtures of different
fatty acids that are administered in the form of triglyc-
erides and phospholipids. The effects of these complex
fatty acid mixtures upon endothelial apoptosis are un-
known and likely different from that of free fatty acids
and simple mixtures of free fatty acids.
In this study, we assessed endothelial cell viability
(including apoptosis and necrosis) following LE sup-
plementation. Interestingly, the effects upon cell viabil-
ity differed between the three LEs. OO-supplemented
cells demonstrated an enhancement in cell viability with a
decreased necrotic cell population. SO-supplemented cells
had no significant alteration in cell viability. In contrast,
FO- supplemented cells demonstrated a significant loss in
cell viability with increased apoptosis and necrosis. This
finding is even more significant when one considers that
the FO emulsion (10% or 10 g/dl) was half the concentra-
tion of the OO and SO emulsions (20% or 20 g/dl). Im-
portantly, fish oil increased apoptosis despite decreasing
NF-κB activation, suggesting that this effect was not medi-
ated directly by NF-κB. The mechanisms responsible for
these effects upon endothelial cell viability require add-
itional study but suggest that LEs modulate the apoptotic
and cell necrotic pathways differently. In-vivo investiga-
tions of the effects of LEs upon endothelial cell viability
are important since thrombosis is a major complication
from use of parenteral nutrition.
Figure 3 Inhibitory effect of lipid emulsion supplementation on
LPS-induced ICAM-1 surface expression. Endothelial cells were
supplemented with varying doses of OO (A), SO (B), or FO (C) for
24 hours under standard tissue culture conditions, followed by a
4-hour stimulation with or without LPS (1 μg/ml). Data are expressed
as the mean ± SD of three determinations. A “*” denotes statistically
significant inhibition from the LPS-stimulated positive control.
Figure 4 Effect of lipid emulsion supplementation on
phosphorylation of NF-κB. Endothelial cells were pretreated with
OO (A), SO (B), or FO (C) for 24 hours under standard tissue culture
conditions, followed by a 4-hour stimulation with or without LPS
(1 μg/ml). Cell lysates were electrophoretically separated in a 4-12%
polyacrylamide gradient gel and transferred onto nitrocellulose
membranes. A phospho-specific antibody to the p65 regulatory
subunit of NF-κB assessed the relative activation state of the enzyme.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as the
protein-loading control.
Harvey et al. Lipids in Health and Disease  (2015) 14:9 Page 12 of 16Vascular endothelium regulates the transmigration of
leukocytes into tissues following infection and/or tissue
damage. Suppression of leukocyte transmigration intosites of infection may impair the ability to clear infec-
tions and heal wounds. On the other hand, exacerbation
of transmigration may result in excessive inflammation
and tissue damage. Leukocytes are recruited to sites of
inflammation via leukocyte-endothelial interactions that
are regulated through a series of adhesion molecules
[11,12,23]. Expression of ICAM-1 and other adhesion
molecules are increased by inflammatory stimuli (i.e.
LPS, TNF-α, IL-1β) [24-26].
In this study, we assessed endothelial inflammatory ac-
tivation by measuring endothelial expression of ICAM-1.
We demonstrated that endothelial cell exposure to LPS
significantly increased cell surface expression of ICAM-1.
We found that exposure to the LEs resulted in different
patterns and degrees of suppression of ICAM-1. All three
LEs suppressed ICAM-1 in a dose-dependent manner.
OO and SO were equally effective at suppressing LPS-
stimulated ICAM-1 expression at the higher doses (0.5%);
however, OO was more effective at the lower LE doses
(0.05, 0.1, 0.25%). Maximal suppression for OO and SO
was approximately 50%. The FO emulsion suppressed
ICAM-1 expression in response to LPS at all doses studied
(0.05-0.5%). Since the lipid concentration of FO was half
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was much greater than that of either OO or SO. In
addition, FO at 0.25% and 0.5% completely suppressed the
LPS-induced expression of ICAM-1. These results would
indicate that FO has a greater anti-inflammatory effect
upon endothelial cell ICAM-1 expression than the other
LEs. However, it should be noted that all three emulsions
demonstrated anti-inflammatory effects and none en-
hanced the ICAM-1 response. The suppression of ICAM-
1 may be beneficial or detrimental, depending upon the
clinical condition. ICAM-1 is an essential component of
leukocyte transmigration into sites of inflammation and
suppression of the response could impair the ability of the
immune response to control infection or repair injured
tissues. On the other hand, suppression might have benefit
during an enhanced inflammatory response associated
with tissue damage.
The suppressant effects of the FO emulsion (high in
omega-3 PUFAs) upon endothelial cell activation are in
agreement with studies using omega-3 free fatty acids (i.
e. DHA and/or EPA) [23,27-35]. Overall, DHA and/or
EPA have been shown to suppress leukocyte adhesion to
activated endothelial cells [23,28-32,35], suppress ex-
pression of adhesion molecules [23,28-31,33-35] and re-
duce activation of NF-κB. SO-based emulsion has no
suppressive effect on endothelial cell activation by LPS.
In contrast, the OO-based emulsion suppressed ICAM-1
expression, which likely results from its complex mix-
ture of different fatty acids.
Previous studies of the inhibitory effects of fish oil
emulsions upon endothelial cell activation (using differ-
ent models than in our study) are consistent with our re-
sults [36-38]. However, reports of the effects of soybean
oil LEs upon endothelial activation are variable with re-
ports of increased effects [36], no effect [37,38], or in-
hibitory effects [39]. Our study is the first report of
suppression of ICAM-1 expression by an olive-oil pre-
dominate LE. Buenestado et al. [39] evaluated the ef-
fects of an olive-oil based and soybean oil-based LE
upon LPS-induced leukocyte-endothelial interactions
in-vivo in rat mesentery using intravital microscopy.
Leukocyte adhesion and emigration were inhibited by
soybean (consistent with our results) but unaffected by
the olive oil-based LE. ICAM-1 expression was not
assessed. Consistent with our findings using an olive-
oil predominate LE, olive oil supplemented oral diets
have been shown to decrease expression of ICAM-1 by
human peripheral blood mononuclear cells in healthy
middle-aged men [40].
Previous studies have demonstrated that LPS, proin-
flammatory cytokines (TNFα, IL-1β), and fatty acids me-
diate endothelial activation (expression of adhesion
molecules such as ICAM-1) via the transcription factor
NF-κB [8,14,24-26,31,41,42] Activation of NF-κB occursvia two major routes [43,44]. In the inactive state, NF-κB
is found in the cytoplasm bound to IkBα, which prevents
it from entering the nucleus. In response to inflammatory
stimuli, IκB kinase (IKK) is activated and phosphorylates
IkBα. Phosphorylated IκBα is subsequently degraded,
allowing for translocation of NF-κB complexes into the
nucleus [45]. However, IKK phosphorylation of IkBα alone
is not sufficient for NF-κB to initiate gene transcription.
Optimal induction of NF-κB target genes also requires
phosphorylation of NF-κB proteins [43,44]. Phosphoryl-
ation enhances NF-κB interactions with co-activator pro-
teins and gene promoter regions [43]. Thus, measurement
of phosphorylated NF-κB serves as an indicator of NF-κB
activation. LPS-induced phosphorylation of NF-κB can
lead to the transcription and subsequent translation of
pro-inflammatory molecules, including ICAM-1 protein
expression.
We measured NF-κB phosphorylation to determine if
it represented a novel molecular mechanism for the ob-
served effects of the LEs upon ICAM-1 expression. This
is the first study that has evaluated NF-κB phosphoryl-
ation by LEs. Neither OO nor SO pretreatment altered
the LPS-induced NF-κB phosphorylation; however, FO-
supplemented endothelial cells exhibited diminished
levels of NF-κB phosphorylation. These data suggest that
FO supplementation decreases ICAM-1 expression
wholly or partially through suppression of NF-κB activa-
tion. The suppression of ICAM-1 by OO and SO do not
appear to involve suppression of NF-κB phosphorylation.
For these emulsions, we speculate that the LE may alter
endothelial cell membrane composition and prevent
ICAM-1 incorporation into the cell membranes. Other
possible mechanisms for suppression of ICAM-1 expres-
sion include interference with co-inducers or co-factors
that interact with NF-κB to promote binding and tran-
scription of the ICAM-1 gene, altered binding of NF-κB
to the ICAM-1 promoter, induction of ICAM-1 inhibitor
proteins, and interference with other transcription factors
that regulate ICAM-1 expression [25]. Further studies are
required to investigate these and other mechanisms for
the diminished cell surface expression of ICAM-1 with
LEs.
EPA and DHA, consistent with our findings using the
fish oil-based LE, EPA and DHA have been demonstrated
to inhibit endothelial adhesion molecule expression and
leukocyte-endothelial adhesion and transmigration by
inhibiting NF-κB activity [28,29,31,46]. On the other
hand, linoleic acid has been reported to activate NF-κB
and induce NF-κB-dependent transcription in endothe-
lial cells [47-49]. However, these results were obtained
with the single fatty acid, linoleic acid, and not the com-
plex lipid emulsion enriched in linoleic acid (i.e.
soybean oil emulsion). Oleic acid and EPA have been
shown to inhibit NF-κB activation induced by saturated
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fatty acid may be able to inhibit the effects of other fatty
acids. Our results using a complex lipid emulsion that
contains high levels of linoleic acid along with other
fatty acids indicates that soybean oil-based LE inhibits
endothelial cell expression of ICAM-1 and has no effect
on NF-κB activation through phosphorylation. Thus,
complex fatty acid lipid mixtures act differently from
purified single fatty acids.
The doses of triglycerides (from the LEs) used in this
study include those normally found in the blood during
fasting, the postprandial state, and in patients receiving
parenteral nutrition with LE. Normal fasting serum tri-
glyceride levels are less than 160 mg/dl [50-52]. Cohen
et al. [51] reported that mean postprandial serum trigly-
ceride levels varied from 140–210 mg/dl in normal
volunteers (fat intake 40–80 grams) while Cohn et al.
[52] reported mean values of 240 mg/dl (females) and
320 mg/dl (males) following 1 g/kg of fat intake. In a re-
view of serum triglyceride levels in patients receiving LE
as a component of parenteral nutrition, 7.6% had trigly-
ceride levels greater than 400 mg/dl [53]. The mean level in
these hypertriglyceridemic patients was 486.8 mg/dl; values
improved when the LE was discontinued (274 mg/dl).
Triglyceride levels in neonates receiving parenteral nu-
trition ranged from 20–536 mg/dl [54]. Others [55,56]
reported mean triglyceride levels of approximately
200 mg/dl in patients receiving parenteral nutrition.
Llop et al. [55] reported that 26.2% of surgical paren-
teral nutrition patients had triglyceride levels greater
than 265 mg/dl. Levels of triglycerides may approach
500 mg/dl (based upon the mean + 2.5 SD) [55]. Most
parenteral nutrition guidelines recommend that serum
triglyceride levels be kept < 400 mg/dl. The dose of tri-
glyceride used in this study for the cell viability,
ICAM-1 modulation, and NF-κB phosphorylation ex-
periments ranged from 0.025% to 0.5% (5–100 mg/dl
for 20% LE; 2.5-50 mg/dl for the 10% LE). These values
range from low to normal triglyceride levels. We used
0.1-10% LEs for the incorporation studies so as to span
the entire physiologic range of triglycerides from very
low levels (0.1%; 10–20 mg/dl), normal fasting and
postprandial levels (1-2%; 100–400 mg/dl), to elevated
levels (5-10%; 500–2000 mg/dl). Importantly, the
endothelial cell viability and activation studies used
triglyceride concentrations that were within normal
serum ranges. However, in vitro experimentation has
limitations and may significantly differ from in vivo
cellular uptake of the lipid emulsion components. Add-
itionally, other physiological factors may affect the
inflammatory status on the endothelial cells in vivo.
Furthermore, in vivo experimentation is necessary to
determine if our in vitro observations translate into an
in vivo model.Conclusions
This study demonstrates that commercial LEs composed
of different oils produce different effects upon endothe-
lial cell functions that include fatty acid uptake and
incorporation, integrity, and inflammatory activation.
Fatty acid incorporation into the cells demonstrated
different cellular localization (i.e. phospholipid vs trigly-
ceride compartments). The OO emulsion improved endo-
thelial cell viability while the FO emulsion decreased cell
viability (the SO emulsion had no effect on viability). Con-
trary to our initial hypothesis, we found that the n-3
PUFA-, n-6 PUFA-, and n-9 MUFA-predominant LEs all
suppressed endothelial cell expression of ICAM-1 (an
indicator of endothelial cell inflammatory response);
however, the omega-3 PUFA emulsion was much more
potent than the other emulsions. In addition, the n-3
PUFA-predominant LE inhibited activation (phosphor-
ylation) of NF-κB, while the soybean and olive/soybean
LEs did not alter NF-κB phosphorylation. These results
suggest that n-3 PUFA-predominant LE inhibits endo-
thelial adhesion molecule expression by a mechanism
that differs from that of n-6 PUFA- or n-9 MUFA-
predominant LEs. Future studies are required to deter-
mine whether the observed in vitro endothelial effects
are predictive of in vivo effects, and whether different
mechanisms of ICAM-1 inhibition have implications
for disease development and progression.
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